Fig. 2
From: BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia
Hybridization assays of BioCode in presence of different target sequences. a BioCode-e13 donor emission in the presence of e13a2 complementary target (white diamonds); b acceptor-ROX emission in the presence of e13a2 complementary target; c BioCode-e13 donor emission in the presence of non-complementary target (black diamonds); d acceptor-ROX emission in the presence of non-complementary target (black diamonds); e BioCode-e13 donor emission in the presence of exon 13 BCR derived target (black squares); f acceptor-ROX emission in the presence of exon 13 BCR derived target (black squares); g BioCode-e13 donor emission in the presence of ABL target (black diamonds); h acceptor-Dy emission in the presence of ABL target (black diamonds). The black arrow represents the addition of the target sequence